Canadian Diabetes & Endocrinology Today https://CanadianDiabetesAndEndocrinologyToday.com/ Catalytic Health en-US Canadian Diabetes & Endocrinology Today 2817-4089 Addressing Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management https://CanadianDiabetesAndEndocrinologyToday.com/article/view/3-s01-Jain <p class="p1"><span class="s1">Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in Canadian endocrinology, affecting up to 70% of those with type 2 diabetes and 75% with obesity. Despite this, routine screening is rare, leading to missed detection and intervention. Advanced fibrosis, observed in 15% of cases, increases the risk of liver and cardiovascular complications. This article addresses the burden of MASLD and the need for systemic screening and patient-centred care to improve outcomes and reduce Canada’s disease burden.</span></p> Akshay Jain Copyright (c) 2025 Canadian Diabetes & Endocrinology Today https://creativecommons.org/licenses/by-nc-nd/4.0 2025-12-16 2025-12-16 2–8 2–8 10.58931/cdet.2025.3s0144